© Reuters.
Eterna Therapeutics (NASDAQ:ERNA), a biotechnology firm, has been notified by The Stock Market of a noncompliance issue regarding its stockholders’ equity. On Monday, the company disclosed that it received a notice from Nasdaq’s Listing Qualifications Staff indicating that its stockholders’ equity fell below the minimum requirement of $2.5 million, reporting a total of $2.2 million as of December 31, 2024.
Under Nasdaq Listing Rule 5550(b)(1), Eterna Therapeutics is required to present a plan by May 3, 2024, outlining measures it will undertake to address the shortfall and regain compliance. If Nasdaq accepts the company’s compliance plan, Eterna may be granted an extension of up to 180 days from the notice date to meet the listing standards.
Should the plan fail to receive approval, Eterna Therapeutics has the right to appeal the decision before a Nasdaq hearings panel. The company’s management is currently evaluating options to resolve the noncompliance and anticipates submitting its plan to Nasdaq by the specified deadline.
The notice from Nasdaq does not immediately affect Eterna’s listing on the stock market; its common stock continues to be traded under the ticker symbol ERNA. Still, the company faces the risk of delisting if it does not regain compliance within the allowed timeframe.
This development is based on the latest 8K filing by Eterna Therapeutics and is a significant regulatory matter that the company must address to maintain its standing on the Nasdaq stock exchange.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read the full article here
